Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-16

Study Completion Date

2026-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing brain surgery (craniotomy). Glioblastoma is the most common and most aggressive form of primary and malignant tumor of the brain. Currently, the standard of care for this disease includes surgical resection, followed by radiation with chemotherapy and tumor treating fields. Despite this aggressive therapy, the survival after finishing treatment remains low and the disease often reoccurs. Unfortunately, the available therapy options for recurrent glioblastoma are minimal and do not have a great effect on survival. AMSCs are found in body fat and when separated from the fat, are delivered into the surgical cavity at the time of surgery. When in direct contact with tumor cells, AMSCs affect tumor growth, residual tumor cell death, and chemotherapy resistance. The use of AMSCs delivered locally into the surgical cavity of recurrent glioblastoma during a craniotomy could improve the long-term outcomes of these patients by decreasing the progression rate and invasiveness of malignant cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

NCT02055196

Adult Anaplastic Astrocytoma Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma +3 more

WITHDRAWN PHASE1

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

NCT02015819

Adult Anaplastic Astrocytoma Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma +4 more

COMPLETED PHASE1

AMG 595 First-in-Human in Recurrent Gliomas

NCT01475006

Advanced Malignant Glioma Anaplastic Astrocytomas Glioblastoma Multiforme

COMPLETED PHASE1

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

NCT01082926

Anaplastic Astrocytoma Anaplastic Ependymoma Anaplastic Meningioma +11 more

COMPLETED PHASE1

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

NCT02192359

Recurrent Anaplastic Astrocytoma Recurrent Anaplastic Oligoastrocytoma Recurrent Anaplastic Oligodendroglioma +4 more

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To establish the maximum tolerated dose (MTD) of locally delivered adipose-derived mesenchymal stem cells (AMSCs) in patients with recurrent glioblastoma (GBM).

SECONDARY OBJECTIVES:

I. To assess the safety and toxicity profile of locally delivered AMSCs in patients with recurrent GBM.

II. To assess overall survival (OS) in recurrent GBM patients treated with locally delivered AMSCs.

III. To assess progression free survival (PFS) in recurrent GBM patients treated with locally delivered AMSCs.

CORRELATIVE OBJECTIVES:

I. To explore the systemic immune response after application of AMSCs through cytokine analysis on peripheral blood samples.

II. To explore the local changes on the brain parenchyma by analyzing tissue at recurrence.

III. To explore the presence of AMSCs on brain tissue at recurrence.

OUTLINE: This is a dose-escalation study.

Patients receive AMSCs intratumorally (IT) and undergo Ommaya reservoir placement during a craniotomy on study. Patients also undergo magnetic resonance imaging (MRI) on study and during follow-up, as well as blood sample, tissue sample and cerebrospinal fluid (CSF) sample collection on study.

After completion of study treatment patients are followed up every 2 months for 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Glioblastoma, IDH-Wildtype Recurrent Astrocytoma, IDH-Mutant, Grade 4 Astrocytoma, Grade IV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (AMSCs)

Patients receive AMSCs IT and undergo Ommaya reservoir placement during a craniotomy on study. Patients also undergo MRI on study and during follow-up, as well as blood sample, tissue sample, and CSF sample collection on study.

Group Type EXPERIMENTAL

Allogeneic Adipose-derived Mesenchymal Stem Cells

Intervention Type BIOLOGICAL

Receive IT

Biospecimen Collection

Intervention Type PROCEDURE

Undergo blood and tissue sample collection

Craniotomy

Intervention Type PROCEDURE

Undergo craniotomy

Magnetic Resonance Imaging

Intervention Type PROCEDURE

Undergo MRI

Ommaya Reservoir Tap

Intervention Type PROCEDURE

Undergo Ommaya reservoir placement for collection of CSF

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Allogeneic Adipose-derived Mesenchymal Stem Cells

Receive IT

Intervention Type BIOLOGICAL

Biospecimen Collection

Undergo blood and tissue sample collection

Intervention Type PROCEDURE

Craniotomy

Undergo craniotomy

Intervention Type PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Intervention Type PROCEDURE

Ommaya Reservoir Tap

Undergo Ommaya reservoir placement for collection of CSF

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Allogeneic Adipose-derived MSCs Allogeneic Adipose-derived Stem/Stromal Cells Allogeneic Mesenchymal Stem/Stromal Cells Biological Sample Collection Biospecimen Collected Specimen Collection incision of the skull Open Craniotomy Magnetic Resonance Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan NMR Imaging NMRI Nuclear Magnetic Resonance Imaging Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) MRIs sMRI Structural MRI Ommaya Reservoir Access

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants \>= 18 years
* Karnofsky Performance Scale (KPS) \>= 60
* Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only
* Patients with a previous histological diagnosis of glioblastoma multiforme, isocitrate dehydrogenase (IDH) wildtype (WT) or astrocytoma, IDH-mutant World Health Organization (WHO) grade IV according to the 2021 WHO classification of tumors of the central nervous system , who are candidates to- and will undergo a redo craniotomy for excision of recurrent tumor
* There is measurable disease according to the immunotherapy response assessment in neuro-oncology (iRANO) criteria
* Serum creatinine and urea \<= 2 times the upper limit of normal (=\< 3 weeks prior to registration)
* Alanine transaminase (ALT), aspartate transferase (AST) and alkaline phosphatase =\< 3 times the upper limit of normal, and bilirubin =\< 2.5 mg/dL (=\< 3 weeks prior to registration)
* Prothrombin time =\< 1.5 times upper limit of normal (=\< 3 weeks prior to registration)
* International normalized ratio (INR) and partial thromboplastin time (PTT) =\< 1.5 times the upper limit of normal (=\< 3 weeks prior to registration)
* Hemoglobin \>= 9 g/dL (=\< 3 weeks prior to registration)
* Platelets \>= 100 x 10\^9/L (=\< 3 weeks prior to registration)
* Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L (=\< 3 weeks prior to registration)
* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Patient or legally authorized representative (LAR) is able to fully understand and provide written and verbal consent for the protocol
* Willingness to provide mandatory blood specimens for correlative research
* Willingness to provide mandatory tissue specimens for correlative research
* Willingness to undergo Ommaya reservoir placement and provide cerebrospinal fluid (CSF) samples for correlative research

Exclusion Criteria

* Patients who are undergoing needle biopsy only or non-eligible for a surgical intervention
* Tumors located solely in the brain stem, midbrain, or thalamus without inclusion/involvement of surrounding brain matter
* Previous treatment with bevacizumab
* Radiographic evidence of leptomeningeal disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No